Risk characterisation

In this guide

In this guide

- 1. Calcidiol supplementation during pregnancy Introduction and Background
- 2. Calcidiol supplementation during pregnancy Toxicokinetics
- 3. Calcidiol supplementation during pregnancy Toxicity
- 4. Calcidiol supplementation during pregnancy Health based guidance values
- 5. Calcidiol supplementation during pregnancy Exposure assessment
- 6. Calcidiol supplementation during pregnancy Risk characterisation
- 7. Calcidiol supplementation during pregnancy Conclusions and Questions
- 8. <u>Calcidiol supplementation during pregnancy List of Abbreviations and</u>
 Technical terms
- 9. Calcidiol supplementation during pregnancy References
- 10. Calcidiol supplementation during pregnancy Search Terms
- 11. Calcidiol supplementation during pregnancy Annex A
- 95. All calcidiol-containing-containing supplements available on the market did not exceed the ACNFP TUL of 40 μ g/day. All supplements currently available on the market with the exception of "D.velop Tablets Adult" were at the EFSA safe intake level of 10 μ g/day. The "D.velop Tablets Adult" exceeded the EFSA safe intake level by 2-fold.
- 96. The highest estimated exposures of calcidiol from food sources only, was 1.1 μ g/day, which is significantly below the ACNFP TUL of 40 μ g/day and the EFSA safe intake level of 10 μ g/day. For food and calcidiol supplements combined, maximum mean exposures of calcidiol exceeded the EFSA safe intake level of 10 μ g/day by 2-fold. The minimum 97.5th percentile intake marginally exceeded the EFSA safe intake level, whereas the maximum 97.5th percentile intake exceeded the EFSA safe intake level by 2.1-fold. However, all mean and 97.5th percentile chronic intakes of calcidiol from food and supplements combined were below the ACNFP TUL of 40 μ g/day. Individuals with a loss of function mutation in enzyme CYP24A1 are more likely to have higher circulating levels of calcidiol in their blood

as this enzyme is responsible for the breakdown of calcidiol and 1,25(OH)2D (Jones et al., 2012) and are therefore more prone to the effects of excessive calcidiol exposure.

- 97. It should also be noted that supplements are likely to be the greatest contributor to calcidiol intake in women of childbearing age, whereas calcidiol intake from the food sources alone is low. Furthermore, not all women of childbearing age consume supplements. Results from the most recent NDNS (years 9-11) report have shown that between 2016-2019 20% of female respondents aged 19-64 years consume vitamin D supplements (Bates et al, 2020).
- 98. The main uncertainties in this assessment were that the NDNS does not specifically include data for pregnant and lactating women, so women of child-bearing age (i.e. 16-49 years) were used as a proxy for these consumer groups, and there is little information on how their diets might differ.
- 99. Further uncertainties include the limited data available on calcidiol's safety in pregnant women.
- 100. Other uncertainties may include background exposure from UVB radiation. Although, exposure to UVB radiation is unlikely to result in adverse serum 25(OH) levels, even when consuming dietary intakes of calcidiol, due to an inbuilt mechanism in the skin. SACN, 2016 stated that "prolonged sunlight exposure does not lead to excess production of cutaneous vitamin D". This is "because endogenously produced pre-vitamin D3 and vitamin D3 are photolyzed to inert compounds" (SACN, 2018), thus preventing conversion into its primary metabolite; 25(OH)D, (i.e. calcidiol) (ACNFP, 2024; Perez-Lopez et al., 2015). SACN also stated that "Vitamin D3 is produced endogenously from 7-dehydrocholesterol (7-DHC) in the skin of humans and animals by the action of sunlight containing UVB radiation (wavelength 280-315 nm) or by artificial UVB light". The 7-DHC in the epidermis is converted to pre-vitamin D3, which reaches a maximum concentration in the skin within a few hours (Holick et al., 1980)" (SACN, 2018).